603520.SS Stock Analysis
60
Uncovered
Zhejiang Starry Pharmaceutical Co Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Zhejiang Starry Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of active ingredient and intermediate X-CT non-ionic contrast agent and fluoroquinolones series. The company is headquartered in Taizhou, Zhejiang and currently employs 1,818 full-time employees. The company went IPO on 2016-03-09. The X-ray contrast medium's major product is iohexol active pharmaceutical ingredient. Quinolone antimicrobial agents' major products are levofloxacin hydrochloride active pharmaceutical ingredient and levofloxacin hemihydrates active pharmaceutical ingredient.